The mechanistic/mammalian target of rapamycin (mTOR), a protein discovered in 1991,
integrates a complex pathway with a key role in maintaining cellular homeostasis. By …

The serine/threonine kinase Akt is a major player in the phosphoinositide 3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway, and its modulation …

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic disorder and constitutes
approximately 25% of cancer diagnoses among children and teenagers. Pediatric patients …

Abstract mTOR activation is a hallmark of T-cell acute lymphoblastic leukemia (T-ALL) and is
associated with resistance to glucocorticoid (GC)-based chemotherapy. We previously …

Despite advancements in cancer management, tumor relapse and metastasis are
associated with poor outcomes in many cancers. Over the past decade, oncogene-driven …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises
from the clonal expansion of transformed T-cell precursors. Although T-ALL prognosis has …

Despite considerable progress in treatment protocols, B‐lineage acute lymphoblastic
leukemia (B‐ALL) displays a poor prognosis in about 15–20% of pediatric cases and about …

The mechanistic target of rapamycin (mTOR) is a central regulator of cell growth and an
attractive anticancer target that integrates diverse signals to control cell proliferation …

BACKGROUND: Chronic inflammation initiated by inflammatory monocytes underlies the
pathogenesis of atherosclerosis. However, approaches that can effectively resolve chronic …

Classification of pediatric T‐cell acute lymphoblastic leukemia (T‐ALL) patients into CIMP
(CpG Island Methylator Phenotype) subgroups has the potential to improve current risk …